Compare LCII & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCII | EWTX |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.3B |
| IPO Year | 1994 | 2021 |
| Metric | LCII | EWTX |
|---|---|---|
| Price | $125.77 | $30.96 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $120.00 | $36.00 |
| AVG Volume (30 Days) | 289.8K | ★ 704.0K |
| Earning Date | 05-19-2026 | 05-27-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 35.18 | N/A |
| EPS | ★ 7.57 | N/A |
| Revenue | ★ $4,122,017,000.00 | N/A |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $4.64 | N/A |
| P/E Ratio | $16.75 | ★ N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $72.31 | $10.60 |
| 52 Week High | $159.66 | $31.82 |
| Indicator | LCII | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.94 | 59.52 |
| Support Level | $120.01 | $28.56 |
| Resistance Level | $151.85 | $31.12 |
| Average True Range (ATR) | 4.53 | 1.42 |
| MACD | -1.99 | -0.12 |
| Stochastic Oscillator | 4.26 | 82.79 |
LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries including buses; and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments; the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.